BAX — Baxter International Inc. stock price, charts and financials

QT78Baxter International Inc.

Baxter International Inc. (NYSE: BAX) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
27.73
+0.18+0.67%
BAXQT78Baxter International Inc.·NYSE
27.73+0.67%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E-EPS (ttm)-2.04Insider Own0.76%Shs Outstand517.00MPerf Week5.31%
Market Cap14.24BForward P/E13.58EPS next Y2.03Insider Trans0.00%Shs Float512.07MPerf Month22.66%
Enterprise Value21.76BPEG0.17EPS next Q0.53Inst Own-Short Float7.19%Perf Quarter57.52%
Income-1.06BP/S1.24EPS this Y198.88%Inst Trans-Short Ratio5.21Perf Half Y26.55%
Sales11.47BP/B2.30EPS next Y0.59%ROA-5.37%Short Interest36.84MPerf YTD44.17%
Book/sh-P/C10.80EPS next 5Y3.54%ROE-16.60%52W High30.20 -8.17%Perf Year22.44%
Cash/sh-P/FCF21.01EPS past 3/5Y-ROIC-1.61%52W Low15.84 75.14%Perf 3Y-37.26%
Dividend Est.0.04 (0.14%)EV/EBITDA29.01Sales past 3/5Y3.79% -0.75%Gross Margin30.08%Volatility4.31% 4.14%Perf 5Y-64.38%
Dividend TTM0.20 (0.72%)EV/Sales1.90EPS Y/Y TTM-60.63%Oper. Margin-2.39%ATR (14)1.20Perf 10Y-42.87%
Dividend Ex-DateAug 28, 2026Quick Ratio1.32Sales Y/Y TTM7.84%Profit Margin-9.27%RSI (14)68.75Recom2.61
Dividend Gr. 3/5Y-23.25% -11.45%Current Ratio1.95EPS Q/Q-5.08%SMA2013.30%Beta0.59Target Price23.43
Payout-17.78%Debt/Eq1.56Sales Q/Q5.34%SMA5024.69%Rel Volume1.16Prev Close27.55
Employees37,500LT Debt/Eq1.63EarningsOct 29SMA20039.88%Avg Volume7.01MPrice27.73
IPO DateOct 27, 1981Option/ShortYes / YesEPS/Sales Surpr.52.78% 5.88%Net Debt/EBITDA10.02Volume8,131,258Change0.67%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-31-26ReiteratedStifel NicolausHold$24$28
Jul-31-26UpgradeCitigroupSellNeutral
Jul-28-26ReiteratedStifel NicolausHold$19$24
Jul-28-26ReiteratedUBSNeutral$19$25
Jul-15-26ReiteratedGoldman SachsNeutral$17$21
Jul-06-26ReiteratedEvercore ISI GroupOutperform$23$24
May-28-26DowngradeCitigroupNeutralSell
May-04-26ReiteratedBarclaysOverweight$25$27
Feb-17-26ReiteratedGoldman SachsNeutral$23$17
Feb-16-26ReiteratedUBSNeutral$21$19
Latest News
Aug-04-26
Aug-04-2608:30AM
Aug-03-26
Jul-31-26
Jul-30-26
Jul-29-26
Jul-27-26
Company

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue11,47011,24410,636
Cost of Goods Sold Incl. D&A8,0207,8656,652
Gross Profit3,4503,3793,984
Selling, General and Administrative Excl. Other2,9322,8902,967
Research and Development512518590
Other Operating Expense280279413
Operating Income-274-30814
Interest Expense292290408
Unusual Expense
Non-Operating Income (Expense)8393105
Net Income Before Taxes-483-505-289
Income Taxes48539537
Consolidated Net Income-1,063-957-649
Net Income From Continuing Operations-968-900-326
Net Income-1,063-957-649
EPS (Recurring)-2.04-1.75-1.27
EPS (Basic, Before Extraordinaries)-2.04-1.75-1.27
EPS (Diluted)-2.04-1.75-1.27
EBITDA7507661,116
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio
Price To Sales Ratio1.250.871.40
Gross Margin30.0830.0537.46
Operating Margin-2.39-2.740.13
Net Margin-9.27-8.51-6.10
Shares Outstanding517513510
Market Capitalization14,3399,80314,872
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$34.11$28.93$23.76$18.59$13.41 Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Mason Jeanne KEVP, Chief HR OfficerMar 01 '24Option Exercise37.1764,4882,397,019206,778Mar 05
Mason Jeanne KEVP, Chief HR OfficerMar 01 '24Sale40.6164,4882,618,858142,290Mar 05
STROUCKEN ALBERT P LDirectorMar 20 '23Option Exercise36.933,930145,13540,765Mar 22
STROUCKEN ALBERT P LDirectorMar 20 '23Sale37.523,930147,45436,835Mar 22
Kunzler JacquelineSVP, Chief Quality OfficerFeb 21 '23Option Exercise37.824,163157,44520,538Feb 23
Kunzler JacquelineSVP, Chief Quality OfficerFeb 21 '23Sale40.503,813154,42716,725Feb 23
Mason Jeanne KSVP, Human ResourcesJan 17 '23Option Exercise18.91118,9542,249,420185,708Jan 19
Mason Jeanne KSVP, Human ResourcesJan 17 '23Sale44.7059,4772,658,622126,231Jan 19
HELLMAN PETER SDirectorApr 05 '22Sale76.024,020305,59427,629Apr 07
STROUCKEN ALBERT P LDirectorApr 05 '22Option Exercise29.524,020118,67038,147Apr 07
STROUCKEN ALBERT P LDirectorApr 05 '22Sale76.024,020305,61234,127Apr 07
HELLMAN PETER Sdirector:Apr 05 '22Option Exercise29.524,020118,67031,649Apr 07
FORSYTH JOHN Ddirector:Apr 01 '22Option Exercise0.001,00501,005Apr 05
FORSYTH JOHN Ddirector:Apr 01 '22Sale77.681,00578,06827,029Apr 05
FORSYTH JOHN DDirectorMar 01 '22Option Exercise29.521,00529,66828,034Mar 03
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.